Two clubs in opposite halves of the table in Ligue 1, eighth-place RC Lens and 14th-place FC Nantes, meet at Stade Bollaert-Delelis on Saturday at 1:00 PM ET. Last time out, RC Lens suffered a 1-0 ...

Election Day is almost here. But in the months and days leading up to the final ballots being cast and results counted, USA TODAY reporters fanned out across the country – road tripping to key ...

MANSFIELD — Roche Bros Supermarkets Inc., a 20-store eastern Massachusetts grocery chain under the Roche Bros., Sudbury Farms and Brothers Marketplace banners, said it has entered into a ...

The U.S. women's national team wrapped up their October schedule with a 3-0 win over Argentina at Louisville's Lynn Family Stadium on Wednesday with a surprise brace from defender Naomi Girma ...

Here’s how it works. Ultra runner David Roche got back on the course this weekend to prove that his Leadville 100 win was no fluke. The runner snatched victory at The Javelina Jundred yesterday, just ...

Oct. 30 (UPI) --USA Today is the latest newspaper to announce it will not make a presidential endorsement before next week's general election. Gannett, which owns USA Today and more than 200 ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed (PDF) the setback as part of a wider ...

FRANKFURT, Oct 23 (Reuters) - The CEO of Roche (ROG.S), opens new tab said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the ...

UCB will ad­vance its an­ti-tau an­ti­body for Alzheimer’s dis­ease so­lo af­ter Roche and Genen­tech walked away from the as­set known as bepranemab.

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.